REVB - REVELATION BIOSCIENCES, INC.

1.25
0.020   1.600%

Share volume: 73,232
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.72%

PREVIOUS CLOSE
CHG
CHG%
$1.23
0.02
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 24%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.10%
1 Month
-14.97%
3 Months
20.77%
6 Months
-56.45%
1 Year
-64.59%
2 Year
-60.82%
Key data
Stock price
$1.25
P/E Ratio 
0.00
DAY RANGE
$1.21 - $1.28
EPS 
-$17.98
52 WEEK RANGE
$0.47 - $3.80
52 WEEK CHANGE
-$63.87
MARKET CAP 
4.738 M
YIELD 
N/A
SHARES OUTSTANDING 
3.720 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
01-28-2025
NEXT EARNINGS DATE
05-09-2025
BETA 
1.12
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$100,367
AVERAGE 30 VOLUME 
$226,918
Company detail
CEO: James M. Rolke
Region: US
Website: revbiosciences.com
Employees: 10
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Revelation Biosciences, Inc. focuses on the development or commercialization of innate immune system therapeutics and diagnostics. The company's lead therapeutic candidate is REVTx-99, an anti-viral nasal drop for the prevention or treatment of respiratory viral infections.

Recent news